Journal
ONCOLOGY REPORTS
Volume 23, Issue 3, Pages 671-676Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/or_00000683
Keywords
cisplatin resistance; head and neck squamous cell carcinoma; Stat3; Notch1
Categories
Funding
- China 973 program [2006CB705600]
- National Scientific Foundation of China [30700253, 30800355]
- China program of Changjiang Scholar and innovative research team in University [IRT 0734]
- China project of SRF [2008101]
- 973 program [2009CB521705]
- 863 program [2006AA02A249]
Ask authors/readers for more resources
Cisplatin is the most important chemotherapeutic agent involved in treatment of head and neck squamous cell carcinoma (HNSCC), but cisplatin resistance in HNSCC is still a serious problem in clinic. The reasons why patients fail chemotherapy are unclear. We examined 25 HNSCC patients who were all tested for cisplatin sensitivity by CD-DST (collagen gel droplet embedded culture-drug Sensitivity) method and expression of Stat3 and Notch1. We found that high expression levels of Stat3 and Notch1 were closely associated with cisplatin resistance respectively (P=0.014, P=0.000). fit addition, cisplatin resistance of HNSCC was decreased after inhibition of Stat3 or Notch signaling in vitro. Our results provide first evidence that both high Stat3 and Notch1 expression are associated with cisplatin resistance in HNSCC patients, Supporting the hypothesis that coactivation of Stat3 and Notch1 by their crosstalk induces the reprogrammed survival pathways in HNSCC responding to chemotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available